160 related articles for article (PubMed ID: 12438271)
1. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene.
Ueno NT; Bartholomeusz C; Xia W; Anklesaria P; Bruckheimer EM; Mebel E; Paul R; Li S; Yo GH; Huang L; Hung MC
Cancer Res; 2002 Nov; 62(22):6712-6. PubMed ID: 12438271
[TBL] [Abstract][Full Text] [Related]
2. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
Liao Y; Zou YY; Xia WY; Hung MC
Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.
Ueno NT; Yu D; Hung MC
Oncogene; 1997 Aug; 15(8):953-60. PubMed ID: 9285690
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer.
Yoo GH; Hung MC; Lopez-Berestein G; LaFollette S; Ensley JF; Carey M; Batson E; Reynolds TC; Murray JL
Clin Cancer Res; 2001 May; 7(5):1237-45. PubMed ID: 11350889
[TBL] [Abstract][Full Text] [Related]
5. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
Ueno NT; Bartholomeusz C; Herrmann JL; Estrov Z; Shao R; Andreeff M; Price J; Paul RW; Anklesaria P; Yu D; Hung MC
Clin Cancer Res; 2000 Jan; 6(1):250-9. PubMed ID: 10656456
[TBL] [Abstract][Full Text] [Related]
6. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
8. E1A oncogene-induced sensitization of human tumor cells to innate immune defenses and chemotherapy-induced apoptosis in vitro and in vivo.
Cook JL; Miura TA; Iklé DN; Lewis AM; Routes JM
Cancer Res; 2003 Jun; 63(12):3435-43. PubMed ID: 12810682
[TBL] [Abstract][Full Text] [Related]
9. Technology evaluation: tgDCC-E1A, targeted genetics/MD Anderson.
Wagner JA
Curr Opin Mol Ther; 1999 Apr; 1(2):266-70. PubMed ID: 11715950
[TBL] [Abstract][Full Text] [Related]
10. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
[TBL] [Abstract][Full Text] [Related]
11. [Effect of E1A gene on in vitro growth inhibition and radiochemosensitivity of lymph node metastasis cells of human head and neck squamous cell carcinoma].
Wang XL; Qian XL; Zhao QZ; Xu ZG; Tang PZ
Ai Zheng; 2003 Nov; 22(11):1140-6. PubMed ID: 14613640
[TBL] [Abstract][Full Text] [Related]
12. In vivo efficacy of folate-targeted lipid-protamine-DNA (LPD-PEG-Folate) complexes in an immunocompetent syngeneic model for breast adenocarcinoma.
Bruckheimer E; Harvie P; Orthel J; Dutzar B; Furstoss K; Mebel E; Anklesaria P; Paul R
Cancer Gene Ther; 2004 Feb; 11(2):128-34. PubMed ID: 14671672
[TBL] [Abstract][Full Text] [Related]
13. Systemic tumor suppression by the proapoptotic gene bik.
Zou Y; Peng H; Zhou B; Wen Y; Wang SC; Tsai EM; Hung MC
Cancer Res; 2002 Jan; 62(1):8-12. PubMed ID: 11782349
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16.
Zhou RR; Jia SF; Zhou Z; Wang Y; Bucana CD; Kleinerman ES
Cancer Gene Ther; 2002 May; 9(5):407-13. PubMed ID: 11961663
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model.
Bartholomeusz C; Itamochi H; Yuan LX; Esteva FJ; Wood CG; Terakawa N; Hung MC; Ueno NT
Cancer Res; 2005 Sep; 65(18):8406-13. PubMed ID: 16166319
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of intratracheal lung cancer development by systemic delivery of E1A.
Chang JY; Xia W; Shao R; Hung MC
Oncogene; 1996 Oct; 13(7):1405-12. PubMed ID: 8875978
[TBL] [Abstract][Full Text] [Related]
17. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
Mewani RR; Tang W; Rahman A; Dritschilo A; Ahmad I; Kasid UN; Gokhale PC
Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.
Cho WK; Seong YR; Lee YH; Kim MJ; Hwang KS; Yoo J; Choi S; Jung CR; Im DS
Mol Ther; 2004 Nov; 10(5):938-49. PubMed ID: 15509511
[TBL] [Abstract][Full Text] [Related]
19. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway.
Bao JJ; Le XF; Wang RY; Yuan J; Wang L; Atkinson EN; LaPushin R; Andreeff M; Fang B; Yu Y; Bast RC
Cancer Res; 2002 Dec; 62(24):7264-72. PubMed ID: 12499268
[TBL] [Abstract][Full Text] [Related]
20. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.
Yu D; Matin A; Xia W; Sorgi F; Huang L; Hung MC
Oncogene; 1995 Oct; 11(7):1383-8. PubMed ID: 7478560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
